Loading...
Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR‐JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d...
Saved in:
| Published in: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Blackwell Publishing Ltd
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055665/ https://ncbi.nlm.nih.gov/pubmed/29603851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13312 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|